Nivalis Therapeutics
VerifiedDeveloping a novel class of disease modifying therapies for patients with cystic fibrosis.
Launch date
Employees
Market cap
-
Net debt
-
Enterprise valuation
$120—180m (Dealroom.co estimates Nov 2014.)
Boulder Colorado (HQ)
Get premium to view all results
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor investor | $0.0 | round | |
| N/A | $0.0 | round | |
| N/A | $0.0 | round | |
N/A | Acquisition | ||
| Total Funding | 000k | ||